Drug Trial Radar · NCT05886868
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
66
Planned (sponsor's estimate)
Start
Oct 24, 2023
Primary completion
Jul 2024
Study completion Feb 2025
Sponsor
- Lead sponsor
- Shanghai Best-Link Bioscience, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first in human study of BL0020, and the primary objective is to evaluate the safety and tolerability, and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of BL0020 as a single agent in patients with advanced solid tumors. This study consists of two parts: Part A (dose escalation stage) and Part B (dose expansion stage). The study includes screening, treatment and follow-up periods. In part A, "3+ 3" will be used for dose escalation. In part B, the dose level and/or enrolled patient population for dose-expansion may be adjusted based on available data on the safety, PK and preliminary efficacy gained from the patients.
Conditions
- Advanced Solid Tumor
Interventions
BL0020Drug
Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle. Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose(MTD)Time frame: Throughout the study for approximately 2 years
- Recommended Phase II Dose(RP2D)Time frame: Throughout the study for approximately 2 years
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Cancer Care Foundation Limited
Sydney, New South Wales, Australia · Active not recruiting
Scientia Clinical Research
Sydney, New South Wales, Australia · Recruiting
Sunshine Coast University Private Hospital
Birtinya, Queensland, Australia · Active not recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.